A new study finds that a common blood test for ovarian cancer may miss some Black and Native American patients, delaying ...

Researchers examined CA-125 levels at diagnosis, defining them as elevated/borderline or negative/normal in 250,749 patients ...

The cancer antigen (CA)-125 test may miss ovarian cancer in some Black and Native American patients, delaying their treatment ...

A new study focusing on the common CA-125 blood test found that some patients were 23 percent less likely to show elevated ...

The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized among regulatory ...

Black and American Indian patients are less likely to have elevated cancer antigen (CA)-125 levels at ovarian cancer ...

On Monday, the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for a key patent application covering Anixa Biosciences, Inc.’s (NASDAQ:ANIX) ovarian cancer vaccine ...

First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer Initiation ...

Mrs. Rao, a health-conscious 55-year-old, was diagnosed with a large ovarian mass after experiencing persistent abdominal ...

Anixa Biosciences (ANIX) announced that the United States Patent and Trademark Office, USPTO, has issued a Notice of Allowance for a key patent ...